Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Sanofi
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Stanford University
Thomas Jefferson University
M.D. Anderson Cancer Center
Instituto Nacional de Cancer, Brazil
Astex Pharmaceuticals, Inc.
Columbia University
Roswell Park Cancer Institute
Indiana University
Shenzhen TargetRx, Inc.
University Hospital, Basel, Switzerland
Indiana University
Bellicum Pharmaceuticals
University of Nebraska
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
GT Biopharma, Inc.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Chinese PLA General Hospital
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Gamida Cell ltd
M.D. Anderson Cancer Center
Novartis
Gamida Cell ltd
M.D. Anderson Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Ciusss de L'Est de l'Île de Montréal
University of Michigan Rogel Cancer Center
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Singapore General Hospital
Bambino Gesù Hospital and Research Institute
Polyphor Ltd.
Singapore General Hospital